- Combination of Palbociclib and Letrozole Shows Promising Results in First-Line Treatment of ER-Positive, HER2-Negative Advanced Breast Cancer
- When to Consider Doxorubicin Alone or in Combination With Ifosfamide for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma?
- Next Generation ALK Inhibitor for ALK-Rearranged Non–Small Cell Lung Cancer
- PRESTIGE Study: Goserelin Given Every 12 vs. 4 Weeks in Premenopausal Women With ER-Positive Advanced Breast Cancer
- ELCC 2014 News: Cabazitaxel Fails to Meet the Primary Endpoint in a Randomised Phase II Study in SCLC Patients
- ELCC 2014 News: Mutational Spectrum of Patients Enrolled Into GALAXY-1 Study
- ELCC 2014 News: A Meta-Analysis of Platinum-Based vs. Single Agent Chemotherapy in NSCLC Patients with Performance Status 2
- ELCC 2014 News: Salvage Therapy With Paclitaxel and Bevacizumab in Patients with Refractory Relapsed SCLC
- ELCC 2014 News: Efficacy and Safety of Targeted Therapy in Elderly Patients With Lung Cancer Adenocarcinoma
- ELCC 2014 News: Diagnosis and Targeting Lung Adenocarcinoma with RET Fusion
- ELCC 2014 News: QoL in ENSURE Study of First-Line Erlotinib vs. Gemcitabine/Cisplatin in Asian Patients with EGFR Mutation-Positive NSCLC
- ELCC 2014 News: Phase I Study of CO-1686 in Patients with EGFR Mutated Recurrent, Advanced NSCLC
- EMA Recommends Granting a Conditional Marketing Authorisation for Vintafolide for the Treatment of Platinum-resistant Ovarian Cancer that Expresses the Folate Receptor
- Idelalisib in Relapsed Indolent Lymphoma
- 2013: A Year of Progress in Oncology
- Promising Results of GOG Study with Bevacizumab for Advanced Cervical Cancer
- Bevacizumab Fails to Improve Overall Survival in First-Line Treatment for Glioblastoma
- How to Reset Strategies to Maximise the Potential of PI3K/AKT/mTOR Inhibitors in Cancer Therapy
- FDA Approves Ibrutinib for Chronic Lymphocytic Leukaemia
- Who are the Originators of Innovative Medicines in the EU?
- SWITCH Study of Efficacy and Safety of Sorafenib/Sunitinib vs. Sunitinib/Sorafenib in the Treatment of mRCC
- Enzalutamide in Chemotherapy-Naive mCRPC
- European Medicines Agency Recommended Marketing Authorisation for 16 Medicines for the Treatment of Cancer in 2013
- European Medicines Agency Recommends Refusal of the Marketing Authorisation for Masitinib
- Ramucirumab in Combination With Paclitaxel Improves Overall Survival in Second Line Treatment for Metastatic Gastric Cancer